ESGO 2024 Insights: "Antibody-Drug Conjugates in Ovarian Cancer"
Disclaimer: On March 22, 2024, the FDA has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.
Login to view comments.
Click here to Login
